Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo
Sponsor: University of Utah
Summary
The investigators central hypothesis is that metformin supplementation will be well-tolerated, safe, and provide patients with improved functional and muscle morphology outcomes following intertrochanteric femur fracture. The objectives will be tested in older adults that sustain a hip fracture and are randomized to receive a daily oral dose (1.5g daily) of metformin or a non-active placebo during 4 months of recovery following surgery.
Official title: A Pilot Study to Assess the Feasibility of a Randomized, Double-blind, Placebo-controlled Trial Investigating Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo
Key Details
Gender
All
Age Range
60 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-09-04
Completion Date
2030-09
Last Updated
2025-09-17
Healthy Volunteers
No
Interventions
Placebo
Placebo tablets will be dispensed to the participants for 119-days.
Metformin
Metformin tablets will be dispensed to the participants for 119-days.
Locations (1)
University of Utah Orthopedics
Salt Lake City, Utah, United States